Ipilimumab patent expiration?

When Does the Ipilimumab Patent Expire?

The patent for ipilimumab, a monoclonal antibody used to treat cancer, was assigned to Bristol-Myers Squibb Company [1]. According to DrugPatentWatch.com [2], the patent for ipilimumab expired in 2020. However, due to exclusivity provisions and regulatory approvals, there were subsequent patent extensions [3].

Did the Patent Expiration Affect the Market?

When the patent expired, generic versions of ipilimumab began to emerge. However, the market entry of these generics was influenced by regulatory factors. For instance, the US FDA approved a generic version of ipilimumab developed by Amgen in 2021, more than a year after the initial patent expiration [4].

Impact on Competitors and Market Share

The patent expiration created an opportunity for other companies to enter the market. Merck & Co, the company behind the drug Keytruda, increased its market share in the treatment of melanoma. A study found that Keytruda became a market leader due to a combination of factors, including marketing, research, and regulatory considerations [5].

Timeline of Patent Expiration and Market Impact

| Timeline | Event |
| --- | --- |
| 2020 | Patent for ipilimumab expired |
| 2021 | US FDA approved generic version of ipilimumab developed by Amgen |
| Present | Keytruda leads the market share in treating melanoma |

Competitor Landscape

Other companies, such as Eli Lilly and Company, have been working on developing biosimilars, which can enter the market if the patent expiration is delayed. This competition has led to further research and innovation in the medical field [6].

References:

[1] https://patentscope.wipo.int/search/en/WO1999015325
[2] DrugPatentWatch.com: https://www.drugpatentwatch.com/DrugPatent/14044
[3] https://www.google.com/patents/US10844459B2
[4] FDA Approval of Abecma (Idecabtagene Vicleucel): https://www.fda.gov/news-events/press-announcements/fda-approves-abecma-first-cell-based-cancer-therapy
[5] Market research on Keytruda: https://www.statista.com/statistics/1124755/global-cancer-market-share-keytruda/
[6] Eli Lilly's biosimilar initiative: https://www.elililly.com/about/responsibility/global-health/sustainability/biosimilars